OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive factors: a new asset deal with significant potential milestones, a promising new program (xPloration) with growing partner interest, and a reduction in operating expenses. Despite increased net loss, the company maintains a strong cash position and has increased its royalty rate. The Q&A session confirmed positive sentiment towards the xPloration program and upcoming technology launch, though some details remain unclear. Overall, the positive elements, including strong partnership growth and strategic initiatives, suggest a likely positive stock movement.
Key Financial Performance
Revenue $3.9 million for Q2 2025, compared with $7.6 million for the same period in 2024, representing a decrease primarily due to lower milestones achieved and lower service revenue. The decrease was partially offset by new xPloration revenue.
Cost and Operating Expenses $20.1 million for Q2 2025, down from $23.9 million in Q2 2024, a decrease driven by lower R&D and G&A expenses, as well as reduced costs associated with small-molecule ion channel programs.
Research and Development Expense $10.9 million for Q2 2025, compared to $13.9 million in Q2 2024, a decrease due to lower stock-based compensation, lower headcount, and reduced external expenses for small-molecule ion channel programs.
General and Administrative Expense $7.7 million for Q2 2025, down from $8 million in Q2 2024, primarily due to lower legal fees and reduced stock-based compensation expense.
Net Loss $15.9 million or $0.15 per share for Q2 2025, compared to $13.6 million or $0.13 per share in Q2 2024, an increase in net loss.
Cash Position $41.6 million as of June 30, 2025, with cash used in the quarter amounting to $2 million.
Active Programs 381 active programs as of Q2 2025, with a year-to-date net increase of 18 programs, more than doubling the net additions from the first half of 2024.
Post-Discovery Stage Programs 61 programs as of Q2 2025, representing 22% growth from the prior year period, with $1.3 billion in contracted remaining potential milestones.
Royalty Rate Average royalty rate increased to 3.36% in Q2 2025, up from 3.2% reported in November 2023, reflecting the value of OmniAb's technologies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
xPloration Partner Access Program: Launched and received strong market response. Sold and installed an xPloration system within weeks of launch. The system is expected to diversify revenue streams and includes recurring revenue from consumables and subscription services.
Geographic Partner Diversification: Steady diversification of partner base beyond the U.S., increasing the reach of the platform.
Headcount Reduction: Reduced headcount from 114 to 87 employees, expected to save approximately $7 million annually.
Operational Efficiencies: Streamlined business practices and leveraged technologies like xPloration to create long-term value.
Strategic Partnerships and Licensing: Signed multiple license agreements with entities like Veraxa Biotech, Duke-NUS, and others. Executed an asset deal with Angelini Pharma for a small-molecule ion channel modulator.
Focus on Scalable Business: Emphasis on workflow efficiencies and technology innovations to support a scalable business model.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for Q2 2025 decreased to $3.9 million from $7.6 million in Q2 2024, primarily due to lower milestone achievements and service revenue, including the discontinuation of a small-molecule ion channel program.
Attrition in Drug Development: Attrition remains a natural part of drug development, with some programs being discontinued or modified in their development stages, such as the Genmab program exiting a Phase I trial in Q2 2025.
Headcount Reduction: The company reduced its headcount from 114 to 87 employees in 2025, following earlier reductions in February, to streamline operations and reduce costs. This may impact operational capacity and employee morale.
Cost Management Challenges: Operating expenses remain high at $20.1 million for Q2 2025, despite reductions in R&D and G&A expenses. The company also incurred one-time expenses of $1 million related to headcount reductions.
Dependence on Partner Milestones: The company’s financial performance is heavily reliant on milestone payments and partner program progress, which are subject to delays or discontinuation.
Economic Uncertainty: The company faces risks from broader economic uncertainties, which could impact partner budgets and the pace of program advancements.
Supply Chain and Manufacturing Costs: The launch of the xPloration platform introduces new manufacturing and supply chain costs, which could pose challenges if demand fluctuates or costs increase.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company expects 2025 revenue to be between $20 million and $25 million.
Operating Expense Guidance for 2025: Operating expenses are projected to be between $85 million and $90 million, with approximately 40% being noncash expenses.
Cash Usage in 2025: Cash usage in 2025 is expected to be lower than in 2024.
Tax Rate Guidance: The tax rate for 2025 is expected to remain at approximately 0% due to a valuation allowance.
xPloration Partner Access Program: The recently launched xPloration Partner Access Program is expected to diversify revenue streams and create new revenue opportunities through the sale of instruments, consumables, and subscription services.
Clinical Development Projections: The company anticipates 5 to 7 new entries into clinical development for novel OmniAb-derived programs in 2025.
Post-Discovery Stage Programs: The number of post-discovery stage programs has grown by 22% year-over-year, with $1.3 billion in contracted remaining potential milestones associated with these programs.
Royalty Rate Increase: The average royalty rate for antibody programs has increased to 3.36% from 3.2% in November 2023, reflecting the value of the company's technologies.
Headcount Reduction: The company has reduced its headcount to 87 employees, down from 114 at the beginning of 2025, resulting in approximately $7 million in annual cash savings.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any trends in large pharma versus small biotech in terms of discovery?
A:The company has seen continued growth in both partners and programs, with contributions from both large pharma and smaller players, as well as academics incubating assets to spin out into companies.
Q:Does the reiterated guidance include any benefit from xPloration?
A:The reiterated guidance does not include any benefit from xPloration. xPloration is expected to be additive and accretive to the business, but the numbers are still small.
Q:Can you provide details on the xPloration pipeline and its progress?
A:The xPloration Partner Access Program was launched in May at the PEGS conference. The company has 100 active partners, and the first instrument was sold and deployed within weeks of the launch. The book of business is filling up nicely, and there is interest from non-partners as well.
Q:What is the timeline for existing partners to join the Access Program, and are there options for data generation without purchasing an instrument?
A:Existing partners can access xPloration through the company’s workflows. Partners with their own wet labs and sufficient campaigns can purchase an xPloration instrument. Non-partners interested in the program must sign a license agreement to become partners before purchasing an instrument.
Q:Can you provide any details on the second technology launch planned for this year?
A:The second technology launch is planned for this year and will be announced at a major scientific conference. It will focus on helping partners discover antibodies more quickly and efficiently, with a lot of novelty.
Q:Does the Janssen trispecific fall into the grandfathered prepaid license bucket?
A:No, the Janssen trispecific does not fall into the grandfathered prepaid license bucket. There are $35 million in milestone payments associated with first sales, similar to the prior bispecific teclistamab.
Q:Can you provide an estimate of the back-end stream of consumable and subscription revenue for xPloration?
A:The company has estimates, but it varies depending on the customer. They are not ready to provide specific numbers at this point.
Q:What proportion of preclinical and beyond assets are derived from the OmniChicken platform, and does it command a higher royalty rate?
A:The OmniChicken platform has contributed to three antibodies entering the clinic. The company has not broken down the 61 post-discovery programs by source technology. The platform generally commands a range of royalties, with an improving average royalty rate.
Q:What is the business plan for xPloration?
A:The business plan involves selling instruments and downstream proprietary consumables, such as chips and plates, as well as software licenses with maintenance.
Q:What are the themes in the programs that partners are exploring?
A:The company sees a diverse range of therapy areas, including oncology, inflammation, fibrosis, renal, dermatology, CNS diseases, and metabolic conditions. There is also a trend of big pharma targeting larger areas with bigger swings.
Q:Review of Unclear Management Responses
A:Management avoided providing specific estimates for the back-end stream of consumable and subscription revenue for xPloration, citing variability depending on the customer. Additionally, they did not break down the 61 post-discovery programs by source technology, leaving some details unclear.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Gustafson OmniAb
JJ
Phase III
Research Division
Slide
University
agreement
deal
development
discovery
distribution partner
economics
efficiency technology
employee
form value
goal
graphic
industry value
instrument
launch xPloration
license
myeloma
number program
others
partner addition
platform
reach
response
screening
stage program
system
throughput
treatment
trial
OABI Transcript
OmniAb, Inc. (OABI) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights significant cost savings and a reduced net loss, despite a slight revenue decline. The Q&A reveals optimism about future milestones, AI integration, and market expansion. Although some management responses were vague, the overall sentiment is positive, with strong emphasis on innovation and potential new revenue streams. The company's strategic focus on efficiency and technology advancements indicates a positive outlook, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary highlights strong financial performance, with a 15% revenue increase, a 25% rise in net income, and improved operating margins. These factors suggest effective cost management and operational efficiency. The caution regarding forward-looking statements is standard but does not overshadow the current positive metrics. Although some milestones have been delayed, the launch of OmniUltra and growth in the xPloration platform present future opportunities. Despite the lack of a market cap, these elements collectively indicate a positive sentiment, predicting a stock price increase of 2% to 8%.
OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary and Q&A indicate mixed sentiments. While there are positives like the xPloration program's potential and reduced expenses, the lack of clear guidance on cash runway and revenue expectations, alongside a slight increase in net loss, tempers optimism. The private placement strengthens the balance sheet, but management's evasiveness on certain details suggests uncertainty. Given these factors, the stock price reaction is likely to be neutral in the short term.
OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlights several positive factors: a new asset deal with significant potential milestones, a promising new program (xPloration) with growing partner interest, and a reduction in operating expenses. Despite increased net loss, the company maintains a strong cash position and has increased its royalty rate. The Q&A session confirmed positive sentiment towards the xPloration program and upcoming technology launch, though some details remain unclear. Overall, the positive elements, including strong partnership growth and strategic initiatives, suggest a likely positive stock movement.
OABI Slides
OABI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
